Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Aardvark Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($2.52) for the year. Cantor Fitzgerald has a "Overweight" rating and a $50.00 price objective on the stock.
AARD has been the subject of several other research reports. Bank of America raised their price objective on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Wall Street Zen raised shares of Aardvark Therapeutics from a "sell" rating to a "hold" rating in a report on Friday. Morgan Stanley began coverage on Aardvark Therapeutics in a report on Monday, March 10th. They set an "overweight" rating and a $29.00 price objective on the stock. Finally, Royal Bank of Canada lowered their target price on Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Aardvark Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.25.
View Our Latest Stock Report on AARD
Aardvark Therapeutics Stock Performance
Shares of NASDAQ:AARD traded up $0.09 during midday trading on Tuesday, reaching $11.77. The company's stock had a trading volume of 12,561 shares, compared to its average volume of 100,141. The stock's fifty day simple moving average is $9.57. Aardvark Therapeutics has a fifty-two week low of $4.88 and a fifty-two week high of $19.58.
Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.01).
Institutional Investors Weigh In On Aardvark Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of AARD. Walleye Capital LLC acquired a new stake in Aardvark Therapeutics during the 1st quarter worth $88,000. Goldman Sachs Group Inc. bought a new position in shares of Aardvark Therapeutics in the 1st quarter worth $153,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Aardvark Therapeutics during the first quarter worth $1,878,000. Braidwell LP acquired a new stake in shares of Aardvark Therapeutics during the first quarter worth $3,755,000. Finally, Cormorant Asset Management LP bought a new stake in Aardvark Therapeutics in the first quarter valued at about $6,009,000.
About Aardvark Therapeutics
(
Get Free Report)
Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
See Also
Before you consider Aardvark Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.
While Aardvark Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
